News | October 03, 2012

Sharp Memorial Investigates Radio Frequency as Possible Treatment for Chronic High Blood Pressure

Hospital is leading trial site in Southern California for randomized trial

October 3, 2012 — When multiple medications prove ineffective, patients with high blood pressure are currently left with few treatment options. Sharp Memorial Hospital was the first on the West Coast to participate in Medtronic's SYMPLICITY HTN-3 clinical trial in March, and is currently the leading trial site in Southern California, to test an experimental medical device that aims to lower high blood pressure by using radio frequency energy to disrupt hyperactive nerves that contribute to the condition.

High blood pressure affects an estimated 40 percent of adults in the United States and can lead to serious heart, kidney and blood vessel damage. Traditional treatments for the condition include oral medications that are meant to be taken on a daily basis for years at a time. These drugs are ineffective in some patients, leaving their high blood pressure dangerously uncontrolled.

In the SYMPLICITY HTN-3 trial, interventional cardiologists thread a small tube in the groin and place a device in the artery leading to the kidney. The device briefly emits radio frequency near renal nerves in an attempt to disrupt hyperactive nerves that may be the root of high blood pressure. Renal nerves communicate information from the kidney to the brain, and vice versa. In people with hypertension, the renal nerves are overactive. Multiple treatments are performed in each artery before the device is removed and, since the procedure is minimally invasive, the patient will typically go home the next day.

"Many of our patients in this trial would not otherwise receive treatment for their high blood pressure," said Raghava Gollapudi, M.D., an interventional cardiologist affiliated with Sharp Memorial. "Medications currently on the market are effective in the great majority of people suffering from hypertension. However, for the small percentage of people who aren't being helped by these pills, SYMPLICITY HTN-3 may be an option."

Principal investigators Gollapudi and Ron Miller, M.D., affiliated with Sharp Memorial Hospital, are currently evaluating patients for the SYMPLICITY HTN-3 trial. The trial is randomized.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init